Oxbryta (voxelotor): Withdrawal from UK market

Pfizer Limited in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) need to inform you that Oxbryta (voxelotor) is being withdrawn from the UK market while a review...
Read More

BREAKING NEWS: UKTS launches the 4th Edition (2023) of their Standards

BREAKING NEWS: UKTS launches the 4th Edition (2023) of their “Standards for the Clinical Care of Treatment of Children and Adult’s living with Thalassaemia in the United Kingdom” Read the...
Read More

Exagamglogene autotemcel for treating sickle cell disease [ID4016] – Extra Documents

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Extra Single Technology Appraisal Exagamglogene autotemcel for treating sickle cell disease Dear stakeholders, 2 additional documents have been added to the technical engagement...
Read More

Exagamglogene autotemcel for treating sickle cell disease [ID4016] – update

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Single Technology Appraisal Single Technology Appraisal Exagamglogene autotemcel for treating sickle cell disease Dear stakeholders, After very careful consideration, we have taken...
Read More

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – Update

Appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia   Dear registrant NICE has taken the decision to postpone the first appraisal committee meeting for this topic. The committee discussion planned...
Read More
NHS Offers Allo Haematopoietic Stem Cell Transplant for Adults with Transfusion Dependent Thalassaemia

NHS Offers Allo Haematopoietic Stem Cell Transplant for Adults with Transfusion Dependent Thalassaemia

BREAKING NEWS: NHS Offers Allo Haematopoietic Stem Cell Transplant (Allo-HSCT) for Adults with Transfusion Dependent Thalassaemia (TDT) Read the full article  
Read More

Progression Decision Point Outcome Exagamglogene autotemcel for treating sickle cell disease [ID4016]

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Progression Decision Point Outcome Exagamglogene autotemcel for treating sickle cell disease Registration  & more information
Read More

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE - Technology Appraisal Committee Meeting Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia Registration  & more information
Read More

Preparations for blood group genotyping for people with sickle cell, thalassemia and rare anaemia

The NHS in England will soon be able to offer blood group and HLA genotyping for the current cohort of people with sickle cell, thalassaemia and transfusion dependent rare anaemias,...
Read More

Educational resources for men experiencing SCD and an associated condition called priapism

Educational resources for men experiencing sickle cell disorder and an associated condition called priapism which have been published today and we thought would be of interest to your members and...
Read More

Sickle cell digital discovery report  -Designing better acute painful sickle cell care

Today we have published a new report  ‘Sickle cell digital discovery report  - Designing better acute painful sickle cell care’. This study set out to fully understand the broad availability...
Read More

Haemoglobinopathy Peer review for Children and Adults

Dear Red Cell Colleagues, I am delighted to let you know that the next round of Haemoglobinopathy Peer review for Children and Adults is going to be starting next year....
Read More

Letter to NHP re blood stocks – 121022

The National Blood Transfusion service has sent out an Amber Alert on stock levels. Direct communications have been made to all NHS Trusts who will be enacting local responses and...
Read More

Apply to be a Committee Members.

Interested parties should submit a short (max 200 word) summary of their area of interest and how they can add to the existing membership. Submissions may be sent directly to...
Read More